SGLT2 Inhibitor HFpEF Data: From Context to Clinical Pearls
By @JavedButler1
#ESCCongress @lamcardio @BSHeartFailure @JJheart_doc @ESC_Journals @ESC_Lavinia @escardio @MKIttlesonMD @ShelleyZieroth @hvanspall @mmamas1973 @aayshacader @pabeda1
The drug ⬇️ the risk of ≥ 50% ⬇️ in eGFR or renal death in EMPEROR-Reduced (HR 0.51; 95% CI 0.33-0.79), but not in EMPEROR-Preserved (HR 0.95; 95% CI 0.73-1.24) #ESCCongress @ESC_Lavinia @escardio
Prior outcomes Trials in #HFpEF and Traditional Mx of HFpEF
What makes EMPEROR-P difference from them?
#ESCCongress @escardio @ESC_Lavinia @lamcardio @JJheart_doc @CMichaelGibson @biljana_parapid @mmamas1973 @ShelleyZieroth @aayshacader @AndrewJSauer @DrRyanPDaly @RyanTedfordMD
#ESCCongress
Risk Factors and Comorbidities : HFpEF Vs HFrEF
@escardio
#ESCCongress
HFpEF has recently been recognized 📌as the single greatest unmet need in CV Medicine
📌The landscape of HFpEF Tx is changing
📌Additional Studies are needed to confirm these results
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.